Wednesday afternoon near market close, Tyler announced that it has been tagged a "leader" and "visionary" in the Gartner Magic Quadrant for Cloud-Based ERP for U.S. Local Government. Tyler Technologies (TYL 0.15%) stock landed in the black, albeit just barely, on the second-to-last trading day of the week. The public-sector-focused enterprise software company managed to squeeze out a slight (0.1%) share price gain, thanks to its landing on a prestigious list. By contrast, the bellwether S&P 500 index closed ...

REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno’s Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DCCR) for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validat ...

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previously Treated with Immune Checkpoint Inhibitor SAN CARLOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with canc ...

New York, New York, May 22, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered offering (the “Offering”) for its client WORK Medical Technology Group LTD (Nasdaq: WOK) (the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China. Under the ...

MORRISTOWN, N.J., May 22, 2025 /PRNewswire/ -- Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboration and innovation with the ultimate goal of bringing medicines and vaccines to patients faster.New Jersey Governor Phil Murphy and Morristown officials were expected to attend the ribbon-cutting ceremony along with Sanofi CEO Paul Hudson and other senior company officials. The Morristown offices are the latest st ...

– Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd – – Encore presentation planned at EHA 2025 Congress – – Kura Oncology to host virtual investor event at 7:30pm ET / 4:30pm PT on June 2nd to discuss the trial results – SAN DIEGO and TOKYO, May 22, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced that an abstract highlighting t ...

-  63% response rate observed among 43 evaluable patients -  79% overall survival rate at 12-months; 9 months median progression-free survival -  Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced interim ...

Core Insights - PDS Biotechnology Corporation is advancing its lead immunotherapy program, Versamune HPV, in combination with pembrolizumab for the treatment of recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC) [2][8] Group 1: Clinical Trial Results - In Phase 2 trials, the median overall survival (mOS) for patients with a Combined Positive Score (CPS) ≥20 is reported at 39.3 months, while for CPS ≥1, it is 30.0 months [1][6] - The ongoing Phase 3 trial (VERSATILE-003) is currently enrolling patients, with a total of 351 patients expected to be accrued [5][6] - The VERSATILE-002 trial shows promising results, with a median follow-up of 18.4 months, indicating one of the longest follow-up periods for this patient population [6] Group 2: Presentation and Publication - Three abstracts summarizing Versamune HPV studies will be presented at the 2025 ASCO Annual Meeting, scheduled for May 30-June 3, 2025 [2][4] - The VERSATILE-002 trial results will be presented by Dr. Jared Weiss, while Dr. Katharine Price will present the ongoing VERSATILE-003 trial details [6] Group 3: Company Overview - PDS Biotechnology is focused on transforming cancer treatment through immunotherapy, particularly targeting HPV16-positive cancers [8] - The company is also developing a triple combination therapy that includes PDS01ADC, an IL-12 fused antibody drug conjugate, alongside standard immune checkpoint inhibitors [8]

Advance Auto Parts (AAP 57.84%) reported its fiscal first-quarter 2025 earnings on May 22, with net sales of $2.6 billion representing a 7% decrease compared to the same period last year. Management completed a rapid store footprint optimization during the period, delivered a near-breakeven adjusted operating margin, and remains focused on supply chain cost leverage, procurement savings, and pro channel strength through 2025 and beyond. It also reaffirmed its full-year guidance for 0.5% to 1.5% of comp sale ...

Core Viewpoint - Abcourt Mines Inc. reported a significant net loss for the third quarter ended March 31, 2025, with no revenues generated during the period, highlighting ongoing financial challenges despite improvements in working capital [1][2]. Financial Results Summary - For the three months ended March 31, 2025, Abcourt reported no revenues, compared to revenues of CAD 255,000 for the same period in 2024 [2]. - Administration expenses increased to CAD 1,068,917 in Q3 2025 from CAD 776,367 in Q3 2024 [2]. - Care and maintenance expenses rose significantly to CAD 692,919 in Q3 2025 from CAD 231,541 in Q3 2024 [2]. - Exploration expenses surged to CAD 4,063,635 in Q3 2025, up from CAD 1,765,615 in Q3 2024 [2]. - The net loss for the three months ended March 31, 2025, was CAD 5,466,608, compared to a net loss of CAD 2,892,142 for the same period in 2024 [2]. - The net loss per share remained at CAD 0.01 for both Q3 2025 and Q3 2024 [2]. - As of March 31, 2025, the company had cash reserves of CAD 937,733, an increase from CAD 757,753 as of June 30, 2024 [2]. - Total assets increased to CAD 16,493,159 as of March 31, 2025, compared to CAD 14,063,983 as of June 30, 2024 [2]. - Non-current liabilities stood at CAD 12,908,748 as of March 31, 2025, up from CAD 12,261,315 as of June 30, 2024 [2]. - Shareholders' equity improved to CAD (3,447,876) as of March 31, 2025, from CAD (6,284,136) as of June 30, 2024 [2]. - Working capital showed improvement, with a negative working capital of CAD (2,172,892) as of March 31, 2025, compared to CAD (4,947,411) as of June 30, 2024 [2]. Company Overview - Abcourt Mines Inc. is a Canadian gold exploration company with properties located in northwestern Quebec, focusing on the Sleeping Giant mine and the Flordin exploration property [5].